Equities analysts expect Aptevo Therapeutics Inc (NASDAQ:APVO) to announce ($0.65) earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Aptevo Therapeutics’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.67). Aptevo Therapeutics reported earnings per share of ($0.53) in the same quarter last year, which would indicate a negative year-over-year growth rate of 22.6%. The company is scheduled to issue its next quarterly earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Aptevo Therapeutics will report full-year earnings of ($2.64) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($2.47). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.72) per share, with EPS estimates ranging from ($3.16) to ($2.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Aptevo Therapeutics.
Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). The business had revenue of $4.07 million during the quarter, compared to the consensus estimate of $3.37 million.
Aptevo Therapeutics opened at $4.50 on Monday, Marketbeat.com reports. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.47 and a quick ratio of 4.39. Aptevo Therapeutics has a one year low of $1.15 and a one year high of $6.35.
Institutional investors have recently added to or reduced their stakes in the business. EAM Investors LLC acquired a new position in shares of Aptevo Therapeutics in the second quarter valued at about $552,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aptevo Therapeutics in the second quarter valued at about $148,000. Acadian Asset Management LLC increased its holdings in shares of Aptevo Therapeutics by 79.0% in the second quarter. Acadian Asset Management LLC now owns 367,509 shares of the biotechnology company’s stock valued at $1,833,000 after purchasing an additional 162,218 shares during the period. Park West Asset Management LLC acquired a new position in shares of Aptevo Therapeutics in the first quarter valued at about $604,000. Finally, Citadel Advisors LLC increased its holdings in shares of Aptevo Therapeutics by 215.4% in the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 27,079 shares during the period. Institutional investors own 34.83% of the company’s stock.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.